Ritter Pharmaceuticals, Inc. Announces End of Phase 2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
151
Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities

LOS ANGELES, CA--(Marketwired - Apr 12, 2017) - Ritter Pharmaceuticals, Inc. ( NASDAQ : RTTR ) (the "Company") today, April 12, 2017, announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017. The Company plans to discuss the results of its recently completed phase 2b/3 trial and phase 3 plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance. The completed phase 2b/3 trial demonstrated several positive topline results and full analysis of the data is underway. The trial was the largest well-controlled clinical study ever conducted in lactose intolerance.

Topline phase 2b/3 trial results provide several positive outcomes 1 :

  • RP-G28 showed a clinically meaningful beneficial effect on patients in both symptom reduction and global patient assessments of benefit.
  • In consultation with the FDA 2 , a composite symptom score was considered appropriate for the primary endpoint. The trial's associated outcomes data support the primary endpoint as an appropriate measurement tool to evaluate and quantify clinically meaningful patient benefit (as defined as a composite symptom reduction of abdominal pain, abdominal cramping, abdominal bloating, and abdominal gas).
  • No serious adverse events (SAEs) related to RP-G28 were reported in the study, further supporting the safety profile previously shown in the phase 2a study.
  • The trial evaluated two different dosing strengths, generating the necessary data to help identify an optimal dose regimen of treatment effect. 

Dr. William Chey, Director of the GI Physiology Laboratory at University of Michigan, commented, "The fact that the Company was able to develop a well-defined clinical outcomes instrument to quantify clinical meaningfulness in lactose intolerance patients is an important outcome of the trial and contribution to the field. We need to remember, there was no standard test to evaluate lactose intolerance symptoms prior to this study. Based on the topline results of the study, I believe this instrument performed well in defining and capturing clinical benefits to patients with lactose intolerance. I am encouraged to see consistency in the data outcome measures and believe that the topline results provide data supporting a treatment benefit of this investigational compound." Dr. Chey further noted, "Based upon these encouraging results, I believe a Phase 3 program can be well-defined and developed from here."

1 Additional topline data results of the phase 2b/3 trial can be found at www.ritterpharmaceuticals.com/investors/events-presentations 2 Ritter Pharmaceuticals held a Type C informational meeting with the FDA in March of 2017 prior to unblinding the phase 2b/3 clinical trial

End of Phase 2 Meeting & Phase 3 Program Plans The end of phase 2 meeting will be an important venue to consult with the FDA on finalizing the Phase 3 clinical program and remaining NDA-enabling package necessary for obtaining commercial approval of RP-G28 for the treatment of lactose intolerance. The Company further plans to discuss many aspects of the phase 2b/3 trial results, including the use of the phase 2b/3 data as supportive for registration and the number of subjects expected in the remaining clinical program for a satisfactory NDA filing.

In preparation for the Phase 3 program, the Company has commenced manufacturing efforts and currently anticipates the initiation of phase 3 in the first half of 2018.

About Ritter Pharmaceuticals Ritter Pharmaceuticals, Inc. ( www.RitterPharma.com , @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.

Forward-Looking Statements This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to our ability to successfully complete a confirmatory phase 3 program that will be adequate to support a NDA submission and to bring RP-G28 to market. Management believes that these forward-looking statements are reasonable as and when made. However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks that the FDA will not agree with our interpretation of the data results from our phase 2b/3 clinical trial and risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process. For a discussion of certain risks and uncertainties affecting Ritter Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Ritter Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

Contact Ellen Mochizuki 310-203-1000 ellen@ritterpharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 15

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 94

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 106

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 82

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 98

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading

Top 5 Most Recently Viewed Articles

Amazon.com: A Detailed Look at Its Sway in Retail Markets

Updated Category News Views 265

Understanding Amazon.com and Its Competitive Landscape In an ever-changing and highly competitive retail space, analyzing key players is vital for investors and industry experts. This article aims to provide an in-depth evaluation of Amazon.com (NASDAQ: AMZN), delving into its performance compared to major competitors in the broadline retail sector. By thoroughly...

Continue Reading
Navigating the AI Landscape: Nvidia and the Future of Technology

Updated Category News Views 210

Nvidia: The Titan Amid the AI Hype Nvidia (NASDAQ: NVDA) has become a central figure in the tech world, particularly in the booming AI sector. However, some critics argue that the excitement surrounding AI is overshadowing the realistic capabilities of the technology. The true concern lies not with Nvidia, which is currently dealing with constraints in compute resources,...

Continue Reading
Market Insights on Automatic Data Processing's Short Interest

Updated Category News Views 150

Understanding Short Interest in Automatic Data Processing Automatic Data Processing's (ADP) short percent of float has recently dipped by 3.97% compared to its previous report. Currently, the company has reported approximately 4.93 million shares sold short, representing 1.21% of its available trading shares. Based on the current trading activity, it would take traders...

Continue Reading
Thesis Gold Inc. Unveils Compelling Drilling Results for Bingo

Updated Category News Views 159

Thesis Gold Inc. Reports Exciting Drilling Results at Bingo Zone Thesis Gold Inc. (TSXV: TAU) has recently revealed outstanding drilling outcomes from its Bingo Zone, marking a pivotal moment in the company’s ongoing exploration at its wholly-owned Lawyers-Ranch Project. This project is nestled within a highly regarded mining region, and the recent discoveries promise...

Continue Reading
October Distributions Announced by Roundhill Investments ETFs

Updated Category News Views 52

Roundhill Investments Announces ETF Distributions Roundhill Investments, a leading ETF sponsor known for its innovative financial products, recently announced the distributions for several of its exchange-traded funds (ETFs) including XDTE, QDTE, and RDTE, effective this October. This news is particularly relevant for investors looking to stay informed about their...

Continue Reading